Medical Devices; General Hospital and Personal Use Devices; Classification of the Diabetes Digital Behavioral Therapeutic Device
FDA classifies diabetes digital behavioral therapeutic devices into class II with special controls, requiring premarket notification (510(k)) and compliance with specific performance testing, clinical data, and labeling requirements.
Aforeworn detected this change in the Healthcare AI Regulation (FDA / ONC) space on July 29, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Manufacturers and developers of diabetes digital behavioral therapeutic devices (software intended to treat diabetes through behavioral interventions). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective 30 days after publication (August 25, 2026). Devices already on the market may need to comply within a reasonable timeframe; FDA may require premarket notification for existing devices.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Healthcare AI Regulation (FDA / ONC) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA reclassified these devices from unclassified to class II, subjecting them to special controls including 510(k) clearance, performance testing, clinical data, human factors validation, and specific labeling.
Who it affects
Manufacturers and developers of diabetes digital behavioral therapeutic devices (software intended to treat diabetes through behavioral interventions).
What you must do
Submit a 510(k) premarket notification for any new or modified device, demonstrating compliance with special controls (e.g., clinical validation, cybersecurity, labeling).
Deadline
Effective 30 days after publication (August 25, 2026). Devices already on the market may need to comply within a reasonable timeframe; FDA may require premarket notification for existing devices.
Never miss a change like this again
Aforeworn watches Healthcare AI Regulation (FDA / ONC) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Healthcare AI Regulation (FDA / ONC)
- HIPAA Security Rule To Strengthen the Cybersecurity of Electronic Protected Health Information
- Health Data, Technology, and Interoperability: ASTP/ONC Deregulatory Actions To Unleash Prosperity
- Nondiscrimination in Health Programs and Activities
- Health Data, Technology, and Interoperability: Certification Program Updates, Algorithm Transparency, and Information Sharing
- Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions; Guidance for Industry and Food and Drug Administration Staff; Availability